The estimated Net Worth of Robert J Terifay is at least 28.8 百万$ dollars as of 10 August 2017. Robert Terifay owns over 1,921 units of Regeneron Pharmaceuticals stock worth over 28,780,520$ and over the last 18 years Robert sold REGN stock worth over 0$.
Sign up
Robert Terifay REGN stock SEC Form 4 insiders trading
Robert has made over 18 trades of the Regeneron Pharmaceuticals stock since 2011, according to the Form 4 filled with the SEC. Most recently Robert exercised 1,921 units of REGN stock worth 99,950$ on 10 August 2017.
The largest trade Robert's ever made was exercising 50,875 units of Regeneron Pharmaceuticals stock on 27 July 2012 worth over 918,803$. On average, Robert trades about 14,647 units every 79 days since 2007. As of 10 August 2017 Robert still owns at least 25,214 units of Regeneron Pharmaceuticals stock.
You can see the complete history of Robert Terifay stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Regeneron Pharmaceuticals
Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over 13,084,686,326$ worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth 2,539,854,760$ . The most active insiders traders include Sanofi、Pharma Ag Novartis、Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of 47,694,347$. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth 381,400$.
What does Regeneron Pharmaceuticals do?
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
What does Regeneron Pharmaceuticals's logo look like?
Complete history of Robert Terifay stock trades at Regeneron Pharmaceuticals
Regeneron Pharmaceuticals executives and stock owners
Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include:
-
P. Roy Vagelos,
Chairman of the Board, Director -
Leonard Schleifer,
President, Chief Executive Officer, Director -
George Yancopoulos,
President, Chief Scientific Officer, Director -
Marion McCourt,
Senior Vice President - Commercial -
Andrew Murphy,
Executive Vice President - Research -
Neil Stahl,
Executive Vice President - Research and Development -
Robert Landry,
Chief Financial Officer, Executive Vice President - Finance -
Daniel Van Plew,
Executive Vice President, General Manager - Industrial Operations and Product Supply -
Dr. George D. Yancopoulos M.D., Ph.D.,
Scientific Founder, Pres, Chief Scientific Officer & Director -
Dr. Leonard S. Schleifer M.D., Ph.D.,
Founder, Pres, CEO & Director -
Dr. George D. Yancopoulos,
Scientific Founder, Pres, Chief Scientific Officer & Director -
Robert E. Landry Jr.,
Exec. VP of Fin. & CFO -
Daniel P. Van Plew,
Exec. VP and GM of Industrial Operations & Product Supply -
Joseph J. LaRosa,
Exec. VP, Gen. Counsel & Sec. -
Dr. Andrew J. Murphy,
Exec. VP of Research -
Arthur Ryan,
Independent Director -
George Sing,
Independent Director -
Christine Poon,
Independent Director -
Michael Brown,
Independent Director -
Huda Zoghbi,
Independent Director -
Joseph Goldstein,
Independent Director -
Bonnie Bassler,
Independent Director -
N. Anthony Coles,
Independent Director -
Marc Tessier-Lavigne,
Independent Director -
Christopher Fenimore,
Vice President, Controller -
Joseph LaRosa,
Executive Vice President, General Counsel, Secretary -
Justin Holko,
VP of Investor Relations -
Bob McCowan,
Sr. VP of IT & Chief Information Officer -
Gerald Underwood,
Sr. VP of Technical Operations -
Christopher R. Fenimore,
Sr. VP, Head of Accounting & Controller -
Patrice Gilooly,
Sr. VP of Quality Assurance & Operations -
Charles A Baker,
Director -
Michael S Aberman,
SVP Strategy Investor Relation -
Sanofi,
-
Robert J Terifay,
EVP Commercial -
Alfred G Gilman,
Director -
Robert Alexander Ingram,
Director -
Eric M Shooter,
Director -
Murray A Goldberg,
SVP Administration & Asst Secr -
Stuart Kolinski,
SVP General Counsel and Secret -
Amerique Du Nord S.N.C. San...,
-
Peter Dworkin,
VP Investor Relations & Commun -
Randall Rupp,
SVP, Manufuring Operations -
Pharma Ag Novartis,
10% owner -
Hans Peter Guler,
VP Clinical Programs -
William Roberts,
VP Reg Dev & Med Safety -
Peter Powchik,
SVP Clinical Development & Reg -
Douglas S Mc Corkle,
VP Controller and Asst Treasur -
Craig B. Thompson,
Director -
Kathryn Guarini,
Director -
David P Schenkein,
Director -
Jason Pitofsky,
VP Controller